Lattice Announces New Low Power FPGA Platform
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced its new low power FPGA platform, Lattice Nexus™. The platform is architected to deliver power-efficient performance that will benefit developers of a wide range of applications, including AI for IoT, video, hardware security, embedded vision, 5G infrastructure and industrial/automotive automation. Lattice Nexus is built with innovations at every level of design, from solutions, to architecture, to circuit, and delivers higher system performance at significantly reduced power consumption.
“The Lattice Nexus platform augments the parallel processing and re-programmability of FPGAs with the power-efficient performance demanded by today’s technology trends, like AI inferencing at the Edge and sensor management. The platform also accelerates the rate at which Lattice will release future products,” said Steve Douglass, Corporate Vice President, R&D, Lattice Semiconductor. “Additionally, the Lattice Nexus platform offers easy-to-use solution stacks targeting high-growth applications that help customers more quickly develop their systems, even if they are not expert in FPGA design.”
To increase ease-of-use for customers, the Lattice Nexus platform provides innovative system-level solutions that combine design software and pre-engineered soft IP blocks with evaluation boards, kits and reference designs to enable them to build their systems more quickly. These solutions target key growth application areas like embedded vision and include solutions like sensor bridging, sensor aggregation and image processing.
The Lattice Nexus platform has innovative architectural features that optimize system performance at industry-leading low power. For example, the platform’s optimized DSP blocks and higher on-chip memory capacity enable power-efficient computing, such as AI inferencing algorithms, and runs twice as fast at half the power of Lattice’s previous FPGAs.
Lattice Nexus also uses innovative circuit design to deliver key capabilities to customers, including programmable power-performance optimization and very fast configuration for instant-on type applications.
Lattice Nexus is developed on high-volume 28 nm fully-depleted silicon-on-insulator (FD-SOI) process technology from Samsung. This innovative technology features 50 percent lower transistor leakage compared to bulk CMOS, and is the best technology for delivering the low power Lattice Nexus platform.
“We are excited to collaborate with Lattice to bring the benefits of our Samsung Foundry 28FDS manufacturing process technology to the low power FPGA market,” said Ryan Lee, Vice President of Marketing at Samsung Foundry. “By combining their innovation and expertise in FPGA fabric design with our industry-leading and differentiated foundry technology, Lattice will continue its leadership in low power FPGAs for years to come.”
For more information, please visit www.latticesemi.com/LatticeNexus. Also, a webcast with more information about Lattice Nexus will be available starting at 1 pm PST on December 10, 2019. Register for the webcast at www.latticesemievent.com.
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005355/en/
Contact information
MEDIA CONTACTS:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
